Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Intellia Therapeutics, Inc. (NASDAQ: NTLA).

Full DD Report for NTLA

You must become a subscriber to view this report.


Recent News from (NASDAQ: NTLA)

FDA signs off on Editas Medicine's IND for gene-editing candidate for LCA10
The FDA has approved Editas Medicine's (NASDAQ: EDIT ) Investigational New Drug (IND) application seeking signoff for clinical studies evaluating genome-editing candidate EDIT-101 for the potential treatment of Leber Congenital Amaurosis type 10 (LCA10), a group of inherited retinal disord...
Source: SeekingAlpha
Date: November, 30 2018 07:47
Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O - Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE Capital Corporation (NYSE:STOR), Ares Commercial Real Estate Corpor...
Source: GlobeNewswire
Date: November, 07 2018 07:35
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov...
Source: SeekingAlpha
Date: November, 02 2018 07:59
The Biotech Bumps
We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...
Source: SeekingAlpha
Date: November, 01 2018 08:00
Intellia Therapeutics' (NTLA) CEO John Leonard on Q3 2018 Results - Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Q3 2018 Earnings Conference Call October 31, 2018 8:00 AM ET Executives Lindsey Trickett – Vice President-Investor Relations John Hayes – Controller John Leonard – Chief Executive Officer Andrew Schiermeier – Execut...
Source: SeekingAlpha
Date: October, 31 2018 14:38
Intellia Therapeutics 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Intellia Therapeutics in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: October, 31 2018 10:40
Intellia Therapeutics misses by $0.04, misses on revenue
Intellia Therapeutics (NASDAQ: NTLA ): Q3 GAAP EPS of -$0.53 misses by $0.04 . More news on: Intellia Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 31 2018 07:32
Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its ...
Source: GlobeNewswire
Date: October, 31 2018 07:30
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2018 results and corporate develo...
Source: GlobeNewswire
Date: October, 30 2018 16:30
Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
CAMBRIDGE, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has named Glenn Goddard its executive vice president and chi...
Source: GlobeNewswire
Date: October, 29 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1216.8416.6317.1416.52420,932
2018-12-1116.6216.4916.8516.30408,609
2018-12-1015.8416.5116.6215.55488,752
2018-12-0716.5015.9216.8015.88382,832
2018-12-0616.0616.5316.7215.80561,776

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1254,659101,86653.6577Short
2018-12-1186,865119,53872.6673Short
2018-12-1053,04284,89362.4810Short
2018-12-0746,69174,53162.6464Short
2018-12-0662,275107,28358.0474Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NTLA.


About Intellia Therapeutics, Inc. (NASDAQ: NTLA)

Logo for Intellia Therapeutics, Inc. (NASDAQ: NTLA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,022,952,089 - 05/11/2018
  • Issue and Outstanding: 43,089,810 - 04/27/2018

 


Recent Filings from (NASDAQ: NTLA)

Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 23 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: NTLA)

Daily Technical Chart for (NASDAQ: NTLA)


Stay tuned for daily updates and more on (NASDAQ: NTLA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: NTLA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NTLA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NTLA and does not buy, sell, or trade any shares of NTLA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/